Quantcast

Latest Applied genetics Stories

2011-06-24 00:00:00

AMSTERDAM, June 24, 2011 /PRNewswire/ -- - Dossier Re-Examination Process Initiated Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera(R) (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD"). Following a recent meeting with the European Medicines Agency's (EMA) Committee for Medicinal...

2011-06-15 00:00:27

DNA relationship testing, primarily for paternity cases, is on the rise in the United States increasing more than 400 percent in the past two decades, according to the latest AABB (American Association of Blood Banks) Annual Report Summary for DNA Relationship Testing. As fathers seek to confirm their relationship to children, either affirming or refuting paternity, they turn to DNA testing facilities including DDC (DNA Diagnostic Center), the largest provider of private paternity and other...

e09197757b9f009c11c519b0d6d67f7c
2011-06-11 09:03:30

Using forensic genetics techniques, the UA's Conservation Genetics Lab is working to protect wild animals and catch the criminals in cases of wildlife crime Wildlife face many threats with spreading urbanization, including habitat loss and inbreeding when populations become fragmented and isolated. It doesn't help that there is a billion-dollar international industry dedicated to the illegal trafficking of wild animals or wild animal parts. The Conservation Genetics Lab at the University of...

2011-06-08 13:45:00

FORT LEE, N.J., June 8, 2011 /PRNewswire/ -- Neurologix, Inc. (OTCBB: NRGX) announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC). Recently completed analysis of new data showed patients treated with NLX-P101 had...

32ac2757cd9ce5ab986778b8a62125de
2011-05-31 10:25:00

An investigation into direct-to-consumer (DTC) genetic tests found flawed and inaccurate results, with each one giving different results, and in some cases arriving at medical predictions that were no more accurate than flipping a coin, a Dutch study has found. The findings of the study will increase calls for tighter regulations around personalized genetics tests which can cost more than $800. Critics decry the tests as a waste of money that could mislead people about their future health,...

2011-05-26 07:05:00

FORT LEE, N.J., May 26, 2011 /PRNewswire/ -- Neurologix, Inc. (OTCBB: NRGX) announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD). Improvements in the Unified Parkinson's Disease Rating Scale (UPDRS) at 12 months for the randomized, double-blind, sham surgery-controlled trial of 45...

2011-05-23 00:00:00

AMSTERDAM, May 23, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today the results from studies exploring the role of adeno-associated viral (AAV) vectors for the efficient delivery of short and micro RNA to inhibit disease by RNA interference. Data related to the future development of an RNAi gene therapy for hypercholesterolemia and Huntington's disease were presented at the recent American Society...

2011-05-19 00:00:00

AMSTERDAM, May 19, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the first quarter of 2011. 1Q 2011 Highlights - Glybera(R): - Responses to Day 180 questions of the EMA/CHMP were submitted on schedule - EMA/CHMP...

2011-05-18 16:34:38

Many gene therapy strategies designed to deliver a normal copy of a gene to cells carrying a disease-causing genetic mutation rely on a modified virus to transfer the gene product into affected tissues. One technology platform that is well suited for in vivo delivery of genes is based on adeno-associated viruses (AAV). As these novel therapies move closer to commercialization, so do the methods for large-scale production and efficient delivery of AAV vectors, which are documented in a series...

2011-05-10 00:00:00

AMSTERDAM, May 10, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, provided today a status update on Glybera (alipogene tiparvovec), its gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD). Following the submission of the Day 180 questions at the end of the first quarter to the European Medicines Agency (EMA) as part of Glybera's Market Authorisation Application...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.